Resultats de la cerca - David M. Hyman

Refinar resultats
  1. 1
    Implementing Genome-Driven Oncology

    Implementing Genome-Driven Oncology per David M. Hyman, Barry S. Taylor, José Baselga

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    A view on drug resistance in cancer

    A view on drug resistance in cancer per Neil Vasan, José Baselga, David M. Hyman

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology

    Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology per Jessica J. Tao, Alison M. Schram, David M. Hyman

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

    Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology per Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim, Ajit Suri

    Publicat 2018
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Clinical tumour sequencing for precision oncology: time for a universal strategy

    Clinical tumour sequencing for precision oncology: time for a universal strategy per Michael L. Cheng, Michael F. Berger, David M. Hyman, David B. Solit

    Publicat 2018
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Toward a More Precise Future for Oncology

    Toward a More Precise Future for Oncology per Yonina R. Murciano‐Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Discovery through clinical sequencing in oncology

    Discovery through clinical sequencing in oncology per Mark T.A. Donoghue, Alison M. Schram, David M. Hyman, Barry S. Taylor

    Publicat 2020
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2–Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

    89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2–Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Negative Primary Bre... per Gary A. Ulaner, David M. Hyman, Serge K. Lyashchenko, Jason S. Lewis, Jorge A. Carrasquillo

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials per David M. Hyman, David B. Solit, Maria E. Arcila, Donavan T. Cheng, Paul Sabbatini, José Baselga, Michael F. Berger, Marc Ladanyi

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer

    Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer per Rachel N. Grisham, Gopa Iyer, Evis Sala, Qin Zhou, Alexia Iasonos, Deborah F. DeLair, David M. Hyman, Carol Aghajanian

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Detailed Echocardiographic Phenotyping in Breast Cancer Patients

    Detailed Echocardiographic Phenotyping in Breast Cancer Patients per Hari K. Narayan, Brian S. Finkelman, Benjamin French, Theodore Plappert, David M. Hyman, Amanda M. Smith, Kenneth B. Margulies, Bonnie Ky

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

    A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours per Alison M. Schram, Leena Gandhi, Monica Mita, Lars Damstrup, Frank Campana, Manuel Hidalgo, Enrique Grande, David M. Hyman, Rebecca S. Heist

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    The role of systemic chemotherapy in the management of granulosa cell tumors

    The role of systemic chemotherapy in the management of granulosa cell tumors per Jane Meisel, David M. Hyman, Anjali R. Jotwani, Qin Zhou, Nadeem R. Abu‐Rustum, Alexia Iasonos, Malcolm C. Pike, Carol Aghajanian

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Detection of an NRAS mutation in Erdheim-Chester disease

    Detection of an NRAS mutation in Erdheim-Chester disease per Eli L. Diamond, Omar Abdel‐Wahab, Elena Pentsova, Laetitia Borsu, April Chiu, Julie Teruya‐Feldstein, David M. Hyman, Marc K. Rosenblum

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  15. 15
    Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies

    Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies per Parisa Momtaz, Elena Pentsova, Omar Abdel‐Wahab, Eli L. Diamond, David M. Hyman, Taha Merghoub, Daoqi You, Billel Gasmi, Agnès Viale, Paul B. Chapman

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

    First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors per Jessica J. Tao, Nicholas A. Cangemi, Vicky Makker, Karen A. Cadoo, Joyce F. Liu, Drew Rasco, Willis H. Navarro, Christopher M. Haqq, David M. Hyman

    Publicat 2019
    Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  17. 17
    Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions

    Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions per Jaclyn F. Hechtman, Ryma Benayed, David M. Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E. Arcila, Snjezana Doğan, David S. Klimstra, Marc Ladanyi, Achim A. Jungbluth

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal Metastases

    Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal Metastases per Robin Guo, Mark Schreyer, Jason C. Chang, S. Michael Rothenberg, Dahlia Henry, Paolo Cotzia, Mark G. Kris, Natasha Rekhtman, Robert J. Young, David M. Hyman, Alexander Drilon

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer per Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martínez, Enaksha Wickremsinhe, Aaron Alan Fink, Volker Wacheck, Kathleen N. Moore

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CT

    Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CT per Gary A. Ulaner, Jorge A. Carrasquillo, Christopher C. Riedl, Randy Yeh, Vaios Hatzoglou, Dara S. Ross, Komal Jhaveri, Sarat Chandarlapaty, David M. Hyman, Brian M. Zeglis, Serge K. Lyashchenko, Jason S. Lewis

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: